24 results
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
only compounds in clinical development will remain subject to regulatory oversight;
Even if we obtain and maintain approval for CC8464 and CT2000 … and adversely affected.
Even if we obtain regulatory approval for CC8464 and CT2000, our compounds will remain subject to regulatory oversight.
Even
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
only compounds in clinical development will remain subject to regulatory oversight;
Even if we obtain and maintain approval for CC8464 and CT2000 … and adversely affected.
Even if we obtain regulatory approval for CC8464 and CT2000, our compounds will remain subject to regulatory oversight.
Even
10-K
2023 FY
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
compounds in clinical development will remain subject to regulatory oversight;
Even if we obtain and maintain approval for CC8464 and CT2000 from … and adversely affected.
Even if we obtain regulatory approval for CC8464 and CT2000, our compounds will remain subject to regulatory oversight.
Even if we
8-K
EX-1.1
CHRO
Chromocell Therapeutics Corp.
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
Accounting Oversight Board, reasonably acceptable to the Representative, and the Company shall continue to retain an independent registered public
424B4
CHRO
Chromocell Therapeutics Corp.
20 Feb 24
Prospectus supplement with pricing info
5:30pm
to regulatory oversight.
Even if we obtain any regulatory approval for CC8464, our lead compound, it will be subject to ongoing regulatory requirements … of Section 404(b) of the Sarbanes-Oxley Act; (ii) we will be exempt from any rules that may be adopted by the Public Company Accounting Oversight Board
424B4
hl0id lsuv
20 Feb 24
Prospectus supplement with pricing info
5:28pm